808
Views
0
CrossRef citations to date
0
Altmetric
Gastroenterology

Fecal microbiota is associated with extraintestinal manifestations in inflammatory bowel disease

ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Article: 2338244 | Received 29 Sep 2023, Accepted 17 Mar 2024, Published online: 22 Apr 2024

References

  • Agrawal M, Christensen HS, Bøgsted M, et al. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. Gastroenterology. 2022;163(6):1–14. doi: 10.1053/j.gastro.2022.07.062.
  • Larsen L, Sandri AK, Fallingborg J, et al. Has the incidence of inflammatory bowel disease peaked? Evidence from the population-based NorDIBD cohort 1978–2020. Am J Gastroenterol. 2023;118(3):501–510.
  • Claytor J, Kumar P, Ananthakrishnan AN, et al. Mild Crohn’s disease: definition and management. Curr Gastroenterol Rep. 2023;25(3):45–51. doi: 10.1007/s11894-023-00863-y.
  • Kayal M, Shah S. Ulcerative colitis: current and emerging treatment strategies. J Clin Med. 2020;9(1):94. doi: 10.3390/jcm9010094.
  • Kumar A, Cole A, Segal J, et al. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol. 2022;15(X):17562848221078456. doi: 10.1177/17562848221078456.
  • Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213.
  • Gerhard R, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi: 10.1053/j.gastro.2021.07.042.
  • Vadstrup K, Alulis S, Borsi A, et al. Extraintestinal manifestations and other comorbidities in ulcerative colitis and Crohn disease: a Danish Nationwide Registry Study 2003–2016. Crohns Colitis 360. 2020;2(3):otaa070. doi: 10.1093/crocol/otaa070.
  • Costrini NV. Decision-making in diagnosis and management of extraintestinal manifestations of inflammatory bowel disease. Gastro Open J. 2022;5(1):4–12. doi: 10.17140/GOJ-5-133.
  • Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541–554. doi: 10.1093/ecco-jcc/jjy191.
  • Agrawal M, Allin KH, Petralia F, et al. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat Rev Gastroenterol Hepatol. 2022;19(6):399–409. doi: 10.1038/s41575-022-00593-y.
  • Caruso R, Lo BC, Núñez G. Host–microbiota interactions in inflammatory bowel disease. Nat Rev Immunol. 2020;20(7):411–426. doi: 10.1038/s41577-019-0268-7.
  • Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–662. doi: 10.1038/s41586-019-1237-9.
  • Mar JS, LaMere BJ, Lin DL, et al. Disease severity and immune activity relate to distinct interkingdom gut microbiome states in ethnically distinct ulcerative colitis patients. mBio. 2016;7(4):e01072-16. doi: 10.1128/mBio.01072-16.
  • Teich N, Weber M, Medizin I. Letter to the Editor: first occurrence of severe extraintestinal manifestations of Crohn’s disease following faecal microbiota transplantation. J Crohns Colitis. 2018;10(10):1254–1255. doi: 10.1093/ecco-jcc/jjw081.
  • Morais LH, Schreiber HL, Mazmanian SK. The gut microbiota–brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19(4):241–255. doi: 10.1038/s41579-020-00460-0.
  • Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2019;216(1):20–40. doi: 10.1084/jem.20180448.
  • Fujimura KE, Sitarik AR, Havstad S, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. 2016;22(10):1187–1191. doi: 10.1038/nm.4176.
  • Essex M, Rios Rodriguez V, Rademacher J, et al. Spondyloarthritis, acute anterior uveitis, and Crohn’s disease have both shared and distinct gut microbiota; 2022.
  • Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66(4):611–619. doi: 10.1136/gutjnl-2015-310500.
  • Larsen L, Drewes AM, Fallingborg J, et al. Touch screens as a tool in patient care in the IBD outpatient clinic. Scand J Gastroenterol. 2016;51(9):1106–1110. doi: 10.1080/00365521.2016.1174879.
  • Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909.
  • Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
  • Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95(April):103208. doi: 10.1016/j.jbi.2019.103208.
  • Jensen TBN, Dall SM, Knutsson S, et al. High-throughput DNA extraction and cost-effective miniaturized metagenome and amplicon library preparation of soil samples for DNA sequencing; 2023.
  • Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335–336. doi: 10.1038/nmeth.f.303.
  • Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583. doi: 10.1038/nmeth.3869.
  • Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(Database issue):D590–D596. doi: 10.1093/nar/gks1219.
  • McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLOS One. 2013;8(4):e61217. doi: 10.1371/journal.pone.0061217.
  • Weedon JO. vegan: community ecology package; 2022. Available from: https://cran.r-project.org/package=vegan
  • Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol. 2012;8(9):e1002687. doi: 10.1371/journal.pcbi.1002687.
  • Kurtz ZD, Müller CL, Miraldi ER, et al. Sparse and compositionally robust inference of microbial ecological networks. PLoS Comput Biol. 2015;11(5):e1004226. doi: 10.1371/journal.pcbi.1004226.
  • McCauley KE, Rackaityte E, LaMere B, et al. Heritable vaginal bacteria influence immune tolerance and relate to early-life markers of allergic sensitization in infancy. Cell Rep Med. 2022;3(8):100713. doi: 10.1016/j.xcrm.2022.100713.
  • Chen J, Wright K, Davis JM, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):43. doi: 10.1186/s13073-016-0299-7.
  • Alexander M, Ang QY, Nayak RR, et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe. 2022;30(1):17–30.e9. doi: 10.1016/j.chom.2021.11.001.
  • Rosero JA, Killer J, Sechovcová H, et al. Reclassification of Eubacterium rectale (Hauduroy et al. 1937) Prévot 1938 in a new genus Agathobacter gen. nov. as Agathobacter rectalis comb. nov., and description of Agathobacter ruminis sp. nov., isolated from the rumen contents of sheep and cows. Int J Syst Evol Microbiol. 2016;66(2):768–773. doi: 10.1099/ijsem.0.000788.
  • Pittayanon R, Lau JT, Leontiadis GI, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930–946.e1. doi: 10.1053/j.gastro.2019.11.294.
  • Rajilić-Stojanović M, Shanahan F, Guarner F, et al. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19(3):481–488. doi: 10.1097/MIB.0b013e31827fec6d.
  • Kabeerdoss J, Jayakanthan P, Pugazhendhi S, et al. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res. 2015;142(1):23–32. doi: 10.4103/0971-5916.162091.
  • Wiredu Ocansey DK, Hang S, Yuan X, et al. The diagnostic and prognostic potential of gut bacteria in inflammatory bowel disease. Gut Microbes. 2023;15(1):2176118. doi: 10.1080/19490976.2023.
  • Liu Q, Li B, Li Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut. 2022;71(5):899–909. doi: 10.1136/gutjnl-2020-323565.
  • Lavelle A, Nancey S, Reimund J-M, et al. Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. Gut Microbes. 2022;14(1):2078620. doi: 10.1080/19490976.2022.
  • Yuan D, Tao Y, Wang H, et al. A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer. Invest New Drugs. 2022;40(5):884–894. doi: 10.1007/s10637-022-01263-1.
  • Yao H, Yang H, Wang Y, et al. Gut microbiome and fecal metabolic alteration in systemic lupus erythematosus patients with depression. Front Cell Infect Microbiol. 2022;12:1040211. doi: 10.3389/fcimb.2022.1040211.
  • Abdugheni R, Wang W, Wang Y, et al. Metabolite profiling of human-originated Lachnospiraceae at the strain level. iMeta. 2022;1(4):1–25. doi: 10.1002/imt2.58.
  • Liu X, Mao B, Gu J, et al. Blautia—a new functional genus with potential probiotic properties? Gut Microbes. 2021;13(1):1–21. doi: 10.1080/19490976.2021.1875796.
  • Libertucci J, Dutta U, Kaur S, et al. Inflammation-related differences in mucosa-associated microbiota and intestinal barrier function in colonic Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G420–G431. doi: 10.1152/ajpgi.00411.2017.
  • Nishino K, Nishida A, Inoue R, et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018;53(1):95–106. doi: 10.1007/s00535-017-1384-4.
  • Sokol H, Jegou S, McQuitty C, et al. Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. Gut Microbes. 2018;9(1):55–60. doi: 10.1080/19490976.2017.1361092.
  • Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, et al. Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye. Indian J Microbiol. 2018;58(4):457–469. doi: 10.1007/s12088-018-0746-9.
  • Choy CT, Chan UK, Siu PLK, et al. A novel E3 probiotics formula restored gut dysbiosis and remodelled gut microbial network and microbiome dysbiosis index (MDI) in Southern Chinese adult psoriasis patients. Int J Mol Sci. 2023;24(7):6571. doi: 10.3390/ijms24076571.
  • Wang C, Xiao Y, Yu L, et al. Protective effects of different Bacteroides vulgatus strains against lipopolysaccharide-induced acute intestinal injury, and their underlying functional genes. J Adv Res. 2022;36(1800):27–37. doi: 10.1016/j.jare.2021.06.012.
  • Steimle A, Michaelis L, Di Lorenzo F, et al. Weak agonistic LPS restores intestinal immune homeostasis. Mol Ther. 2019;27(11):1974–1991. doi: 10.1016/j.ymthe.2019.07.007.
  • Waidmann M, Bechtold O, Frick J-S, et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology. 2003;125(1):162–177. doi: 10.1016/S0016-5085(03)00672-3.
  • Senthakumaran T, Moen AEF, Tannæs TM, et al. Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in cancers, adenomatous polyps, and healthy controls. Eur J Clin Microbiol Infect Dis. 2023;42(3):305–322. doi: 10.1007/s10096-023-04551-7.
  • Mills RH, Dulai PS, Vázquez-Baeza Y, et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022;7(2):262–276. doi: 10.1038/s41564-021-01050-3.
  • Anderson A, Cherfane C, Click B, et al. Monocytosis is a biomarker of severity in inflammatory bowel disease: analysis of a 6-year prospective natural history registry. Inflamm Bowel Dis. 2022;28(1):70–78. doi: 10.1093/ibd/izab031.
  • Singla MB, Eickhoff C, Betteridge J. Extraintestinal manifestations are common in obese patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(9):1637–1642. doi: 10.1097/MIB.0000000000001187.